These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 12805239)

  • 1. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
    Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
    Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme.
    Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V
    FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
    van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
    Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of domain-selective angiotensin I-converting enzyme inhibitors.
    Redelinghuys P; Nchinda AT; Sturrock ED
    Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do studies with ACE N- and C-domain-selective inhibitors provide evidence for a non-ACE, non-chymase angiotensin II-forming pathway?
    Husain A; Li M; Graham RM
    Circ Res; 2003 Jul; 93(2):91-3. PubMed ID: 12881473
    [No Abstract]   [Full Text] [Related]  

  • 7. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
    Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
    J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.
    van Esch JH; van Gool JM; de Bruin RJ; Payne JR; Montgomery HE; Hectors M; Deinum J; Dive V; Jan Danser AH
    J Hypertens; 2008 Apr; 26(4):706-13. PubMed ID: 18327080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
    Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
    Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE.
    Ceconi C; Francolini G; Olivares A; Comini L; Bachetti T; Ferrari R
    Eur J Pharmacol; 2007 Dec; 577(1-3):1-6. PubMed ID: 17716647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-domain angiotensin I converting enzyme (kininase II): characterization and properties.
    Deddish PA; Wang LX; Jackman HL; Michel B; Wang J; Skidgel RA; Erdös EG
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1582-9. PubMed ID: 8968386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiotensin converting enzyme (kininase II). Molecular and physiological aspects].
    Costerousse O; Jaspard E; Allegrini J; Wei L; Alhenc-Gelas F
    C R Seances Soc Biol Fil; 1992; 186(6):586-98. PubMed ID: 1339589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats.
    Stanziola L; Greene LJ; Santos RA
    Am J Hypertens; 1999 Oct; 12(10 Pt 1):1021-9. PubMed ID: 10560789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selectivity of converting-enzyme inhibitors for angiotensin I versus bradykinin hydrolysis reactions.
    Brooks RR; Miller KE; Jones SM; Burns RH; Huang CT
    J Pharm Sci; 1990 May; 79(5):384-8. PubMed ID: 2161922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE.
    Deddish PA; Marcic B; Jackman HL; Wang HZ; Skidgel RA; Erdös EG
    Hypertension; 1998 Apr; 31(4):912-7. PubMed ID: 9535414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin II and bradykinin inhibition in rat reduced-size liver transplantation.
    Padrissa-Altés S; Franco-Gou R; Boillot O; Serafín A; Rimola A; Arroyo V; Rodés J; Peralta C; Roselló-Catafau J
    Liver Transpl; 2009 Mar; 15(3):313-20. PubMed ID: 19242996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides.
    Cotton J; Hayashi MA; Cuniasse P; Vazeux G; Ianzer D; De Camargo AC; Dive V
    Biochemistry; 2002 May; 41(19):6065-71. PubMed ID: 11994001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.